Literature DB >> 1691237

The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells.

S R Riddell1, P D Greenberg.   

Abstract

Antigen-specific T cell clones are useful reagents for studies of the fine specificity of antigen recognition and of potential therapeutic use in adoptive immunotherapy for human viral and malignant diseases. Culture methods which require antigen and APC for stimulation can be problematic for the generation and long-term growth of human virus and tumor-specific T cells. We have developed an alternative culture method using monoclonal antibodies to T cell activation molecules, CD3 and CD28, as stimulation to efficiently grow CD4+ and CD8+ antigen-specific T cells from single progenitors and expand T cell clones in long-term culture. This method alleviates the requirement for large amounts of viral or tumor antigens and MHC compatible APC to sustain the growth of virus and tumor-specific T cell clones, and, as demonstrated for CD8+ CMV-specific cytotoxic T cells, overcomes the difficulties cloning CD8+ T cells using virally infected cells as antigen-presenting cells. T cell clones generated and maintained with monoclonal antibody stimulation are rapidly expanded and retain antigen-specific responses after 3 months in culture, suggesting this approach may prove useful for growing large numbers of antigen-specific T cell clones for cellular immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1691237     DOI: 10.1016/0022-1759(90)90210-m

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  150 in total

1.  T cell receptor-induced activation and apoptosis in cycling human T cells occur throughout the cell cycle.

Authors:  M Karas; T Z Zaks; J L Liu; D LeRoith
Journal:  Mol Biol Cell       Date:  1999-12       Impact factor: 4.138

2.  Nonmyeloablative immunosuppressive regimen prolongs In vivo persistence of gene-modified autologous T cells in a nonhuman primate model.

Authors:  C Berger; M L Huang; M Gough; P D Greenberg; S R Riddell; H P Kiem
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

3.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.

Authors:  C Yee; J A Thompson; D Byrd; S R Riddell; P Roche; E Celis; P D Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-11       Impact factor: 11.205

4.  Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes.

Authors:  L J Cooper; M Kalos; D A Lewinsohn; S R Riddell; P D Greenberg
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

5.  Antigen-independent acquisition of MHC class II molecules by human T lymphocytes.

Authors:  Anita H Undale; Peter J van den Elsen; Esteban Celis
Journal:  Int Immunol       Date:  2004-09-06       Impact factor: 4.823

Review 6.  Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.

Authors:  Richard Wu; Marie-Andrée Forget; Jessica Chacon; Chantale Bernatchez; Cara Haymaker; Jie Qing Chen; Patrick Hwu; Laszlo G Radvanyi
Journal:  Cancer J       Date:  2012 Mar-Apr       Impact factor: 3.360

7.  Phenotypes of Th lineages generated by the commonly used activation with anti-CD3/CD28 antibodies differ from those generated by the physiological activation with the specific antigen.

Authors:  Cuiyan Tan; Lai Wei; Barbara P Vistica; Guangpu Shi; Eric F Wawrousek; Igal Gery
Journal:  Cell Mol Immunol       Date:  2014-03-03       Impact factor: 11.530

8.  IL-17 secreted by tumor reactive T cells induces IL-8 release by human renal cancer cells.

Authors:  Takashi Inozume; Ken-ichi Hanada; Qiong J Wang; James C Yang
Journal:  J Immunother       Date:  2009 Feb-Mar       Impact factor: 4.456

9.  Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma.

Authors:  Steven A Rosenberg; James C Yang; Paul F Robbins; John R Wunderlich; Patrick Hwu; Richard M Sherry; Douglas J Schwartzentruber; Suzanne L Topalian; Nicholas P Restifo; Armando Filie; Richard Chang; Mark E Dudley
Journal:  J Immunother       Date:  2003 Sep-Oct       Impact factor: 4.456

10.  Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy.

Authors:  David M Barrett; Nathan Singh; Xiaojun Liu; Shuguang Jiang; Carl H June; Stephan A Grupp; Yangbing Zhao
Journal:  Cytotherapy       Date:  2014-01-16       Impact factor: 5.414

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.